-

J&J-Stop TB Partnership Deal a Positive Step but More Is Needed, says AHF

LOS ANGELES--(BUSINESS WIRE)--With Johnson and Johnson (J&J) recently granting permission to Stop TB Partnership to distribute its generic TB drug bedaquiline (SIRTURO) to the majority of low- and middle-income countries, AIDS Healthcare Foundation (AHF) applauds Stop TB Partnership and the TB community overall for their strong leadership and advocacy in inking this vital agreement. While the deal is a positive step, AHF agrees with advocates, including Médecins Sans Frontières and others, that this is a short-term solution and urges J&J to do more for other lower-income countries that still lack access.

“Tuberculosis kills 1.6 million people annually and remains the leading cause of death for people living with HIV. We are glad to see steps in the right direction with the licensing agreement between J&J and Stop TB Partnership and hope the pharma giant continues to set a positive example for other drug manufacturers to follow for improved access to intellectual property to produce more affordable generic medicines,” said Terri Ford, Chief of Global Advocacy and Policy at AHF. “That said, this doesn’t let J&J off the hook for its past profiteering with its COVID-19 vaccine and other drugs. It shouldn’t take a massive advocacy campaign by civil society organizations for pharmaceutical companies to put lives before profit.”

While AHF is cautiously optimistic, details of this agreement must be made public. It is being reported that countries in Eastern Europe and Central Asia, which have some of the world’s highest burden of drug-resistant TB, are left out of the deal. AHF urges J&J to grant unfettered access to all countries that need this lifesaving medicine.

About AIDS Healthcare Foundation (AHF)

AIDS Healthcare Foundation, the largest global AIDS organization, currently provides medical care and/or services to over 1.7 million people in 45 countries worldwide in the US, Africa, Latin America/Caribbean, the Asia/Pacific Region and Europe. To learn more about AHF, please visit our website: www.aidshealth.org, find us on Facebook: www.facebook.com/aidshealth and follow us on Twitter: @aidshealthcare and Instagram: @aidshealthcare.

Contacts

Ged Kenslea, Senior Director Communications, AHF
+1.323.308.1833 work
+1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

AIDS Healthcare Foundation


Release Versions

Contacts

Ged Kenslea, Senior Director Communications, AHF
+1.323.308.1833 work
+1.323.791.5526 mobile
gedk@aidshealth.org

Denys Nazarov, Director of Global Policy & Communications, AHF
+1 323.308.1829
denys.nazarov@aidshealth.org

More News From AIDS Healthcare Foundation

AHF Hails Introduction of Protect 340B Act of 2026

WASHINGTON--(BUSINESS WIRE)--AHF Hails Introduction of Protect 340B Act of 2026...

AHF Urges African Nations to Take Charge of Medicines Regulation

KIGALI, Rwanda--(BUSINESS WIRE)--With more than 20 African Union Member States yet to ratify the African Medicines Agency (AMA) Treaty, AIDS Healthcare Foundation (AHF) calls on African governments to accelerate ratification and regulatory harmonisation to expand access to affordable medicines and unlock Africa’s pharmaceutical manufacturing potential.The call comes as AMA convenes its inaugural week in Kigali, Rwanda, from 25–30 October 2026, against a backdrop of continued dependence on import...

Treatment = Life: AHF Reaches 2 Million Patients in Care in Africa

KAMPALA, Uganda--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) has surpassed 2 million patients in care across 15 African countries, marking a historic achievement 25 years after beginning its first programs outside the United States in South Africa and Uganda. With programs in four additional countries expected to launch in 2027, AHF is recognizing the communities and partnerships behind this progress while calling for urgent action to close persistent gaps in the HIV response. AHF’s work...
Back to Newsroom